Immune thrombocytopenic purpura (ITP) is an autoimmune disease that affects thousands of Americans each year. The resulting thrombocytopenia, which develops from destruction of platelets (PLT) by anti-PLT autoantibodies (APAb), is often associated with hemorrhagic complications. Existing therapies are not effective and are associated with significant morbidity. Recently, a new treatment modality using plasmapheresis with a Protein-A column has shown some clinical promise. Yet, although this method would remove the pathogenic APAb, it would also deplete protective antibodies, thereby weakening the body's selfdefense system. Because about 80% of patients with ITP develop APAb against the GPIIb/IIIa antigens on PLT, a novel approach of attaching a GPIIb/IIIa-linked bioreactor with an extracorporeal circuit is suggested herein to achieve highly effective/specific APAb removal and overcome shortcomings of plasmapheresis in treating ITP. A hollow fiber-based bioreactor device was fabricated, and GPIIb/IIIa antigens were immobilized onto the inner lumens of the hollow fibers by using the epichlorohydrin activation method. An optimized bioreactor containing a loading of 1.63 mg GPIIb/IIIa/g fibers and adsorption capacity of 1.9 mg 7E3/g fibers was developed. Preliminary proof-of-concept investigation using a 7E3-induced thrombocytopenic rat model (which mimicked clinical ITP) was carried out. A complete (100%) return of PLT counts to their initial levels was observed in rats within 6 h after the GPIIb/IIIa bioreactor treatment. In addition, a rapid restoration of WBC counts in the treated rats was also found. These preliminary findings shed light of promise of using the GPIIb/IIIa bioreactor approach in achieving highly improved ITP therapy.
INTRODUCTION
Immune thrombocytopenic purpura (ITP) is a common autoimmune disease with an estimated incidence rate of 10 -125 per million persons each year. 1 Thrombocytopenia in ITP develops as a result of an enhanced destruction of platelets (PLT), which is precipitated by the interaction of autoantibodies and PLT antigens. 2 The resulting thrombocytopenia is often dramatic and associated with a variety of hemorrhagic sequelae, including epistaxis, oral mucosal bleeding, petechiae, hematuria, gastrointestinal bleeding, and intracranial hemorrhage.
Currently accepted treatments for ITP include pharmacological immunosuppression, splenectomy, and intravenous immunoglobulin (IVIG) therapy, which includes administration of a heterogeneous pool of human IgG, IgM, and IgA. Unfortunately, pharmacological immunosuppression places patients at risk for the development of opportunistic infections and, for most patients, is not able to maintain platelet counts Ͼ30 ϫ 10 9 /L, the value typically accepted as sufficient to provide prophylaxis against severe hemorrhage. On the other hand, splenectomy is associated with considerable morbidity and incomplete efficacy, particularly in patients with chronic ITP. 3 Subsequently, Imbach and coworkers reported that large doses of IVIG increases platelet counts in patients with ITP. 4 The efficacy of IVIG was further confirmed by a number of additional studies. [5] [6] [7] [8] [9] However, IVIG effects are typically short-lived, and the exceptionally high cost of this therapy prohibits the possibility for long-term applications to ITP patients with chronic disease. 10, 11 In addition, this IVIG treatment is beset by certain serious complications. [12] [13] [14] [15] [16] [17] [18] Several new therapeutic modalities are currently under investigation for the treatment of ITP, including 1) application of Protein-A immunoadsorption by using a PROSORBA column 19 ; 2) administration of recombinant thrombopoietin 20, 21 ; and 3) administration of immunoglobulin with a high titer of Anti-Rho (D) antibodies. 22, 23 Nevertheless, these experimental therapies have all encountered significant shortcomings and risks. For instance, given the evidence that antiplatelet antibodies (APAb) are responsible for the increased rate of PLT destruction observed in ITP, immunoadsorptive plasmapheresis has been developed to accelerate the removal of pathogen antibodies. Indeed, this method using the PROSORBA column has been approved by the Food and Drug Administration (FDA) for clinical use in treatment of ITP. 19, 24, 25 The PROSORBA column is made of silica gel containing immobilized Protein-A, a bacterial protein that binds the Fc region of immunogammaglobulin with high affinity. 26 Although this PROSRBA column removes pathological antibodies and immune complexes from the patient, it also depletes protective antibodies, thereby weakening the body's self-defense system and increasing patient susceptibility to opportunistic infections. In addition, Protein-A therapy has also been associated with a variety of thrombotic disorders including stroke. 27, 28 In this work, we proposed a novel bioreactor approach, designed to specifically remove APAb from blood, to overcome the limitations of extracorporeal APAb removal by the nonspecific Protein-A column. Because Ͼ80% of patients with ITP develop antibodies directed against GPIIb/IIIa of PLT, 29 GPIIb/IIIa was selected as the specific antigen for the development of this bioreactor.
The bioreactor developed herein consists of a hollow fiber-based device consisting of the GPIIb/IIIa antigens that are covalently coupled to the inner lumens of the hollow fibers by using the well-established epichlorohydrin activation method. 30, 31 Several design parameters were characterized to optimize the antigen-loading and adsorption capacity of the bioreactor. Preliminary in vivo studies involving rats were also carried out to provide proof-of-concept of this novel bioreactor-based approach to treat ITP. 
MATERIALS

METHODS
Fabrication of the bioreactor device
The hollow fibers were cut to a length of 10 cm, measured to a dry weight of 1 g, and then bonded together with silicone. After allowing the silicone to dry and harden at room temperature, the tips of the fiber bundle were cut to remove any silicone blockage of the fiber openings. The bundle was then housed in a glass tube (inner diameter ca. 1.2 cm) that is fitted with a luer connector at each end. Figure  1 presents an illustration of the bioreactor device. The prepared bioreactor possesses hemodynamic characteristics that mimic clinically used hemodialyzers.
Activation of the hollow fiber-based bioreactor
The hollow fiber-based bioreactor fabricated above was activated by circulating 10 mL of 0.8M sodium hydroxide, containing 0.5 mL epichlorohydrin, for 2 h at 40°C. The bioreactor was then washed repeatedly with a large volume of ddH 2 O until no epichlorohydrin could be detected. To determine the presence of epichlorohydrin, 2 mL of flow through water was put into a glass tube followed by the addition of 1 mL of 1.3M sodium thiosulfate solution and 1 drop of bromothymol blue solution (indicator). A blue color indicated the presence of epichlorohydrin, whereas a yellow color signified a complete removal of this activating agent.
Determination of epoxy groups on the activated hollow fibers
Content of the epoxy groups on the epichlorohydrin-activated hollow fibers was determined by titration. 32 Briefly, the hollow fiber bioreactor was first washed with ddH 2 O. After removing the water, 1.3M sodium thiosulfate solution was circulated through the bioreactor for a half hour at room temperature. The epoxy content in the bioreactor was then determined by titration of the rinsed thiosulfate solution with 0.01M hydrochloric acid by using bromothymol blue as the indicator. The change of color from blue to yellow indicates the titration end point where the moles of hydrochloric acid consumed were equal to the moles of epoxy in the bioreactor.
Coupling of GPIIb/IIIa onto the activated hollow fiber bioreactor
GPIIb/IIIa solution (0.5 mg/mL in 0.15M PBS buffer, pH 8.3) was circulated through the bioreactor for 12 h at 40°C. The bioreactor was then washed with 0.15M PBS buffer (pH 7.4). Unreacted epoxy groups were blocked by reacting with 1M ethanol amine, in 0.1M borate buffer at pH 8.0, for overnight at room temperature. The bioreactor was then washed with ddH 2 O, PBS buffer (pH 7.4), NaCl (2M), and then stored at 40°C. The amount of coupled GPIIb/IIIa was determined by measuring the GPIIb/IIIa concentration in solution before and after circulation, according to the method of Bradford.
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Coupling of albumin onto activated hollow fiber
An albumin bioreactor was developed to assess the nonspecific binding of monoclonal antiplatelet antibody, 7E3. Albumin was coupled onto epichlorohydrin-activated hollow fibers according to the same procedures described above. The amount of immobilized albumin was determined by measuring the initial and final albumin concentrations in the coupling solution.
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Leakage of coupled GPIIb/IIIa
To determine the degree of leakage of GPIIb/IIIa from the bioreactor, PBS buffer (10 mL, pH 7.4) was circulated through the GPIIb/IIIa-coupled bioreactor at room temperature over a period of 4 days. The PBS elution was carried out, by using 100 L fresh PBS buffer, every 30 min for 3 h and then everyday for 4 days. Leakage was determined by measuring the GPIIb/IIIa concentration in the eluting solution by using the Bradford protein assay method. 33 The degree of leakage was expressed as the percentage of eluted GPIIb/IIIa relative to the amount of immobilized GPIIb/ IIIa.
In vitro adsorption test of monoclonal antiplatelet antibody (7E3)
The adsorption of 7E3 antibodies on the GPIIb/IIIa bioreactor was examined in vitro. In brief, the bioreactor was washed with PBS buffer (pH 7.4) at a flow rate of 5 mL/min. The 7E3 antibody solution (0.25 mg/mL) was then pumped through the bioreactor at the same flow rate for 20 min at room temperature. The amount of 7E3 antibodies adsorbed onto the bioreactor was determined by measuring 7E3 concentrations before and after the adsorption process according to the method of Bradford. 33 The adsorption of 7E3 onto a sham bioreactor was used as the control to assess the degree of nonspecific adsorption of 7E3 onto plain hollow fibers.
Desorption of 7E3 and repeated uses of the bioreactor
Desorption of 7E3 was studied by circulating a 0.1M amino acetic acid solution through the 7E3-adsorbed GPIIb/ IIIa bioreactor at room temperature for 2 h. The final 7E3 concentrations in the eluant were determined.
To test the reusability of the GPIIb/IIIa bioreactor, the 7E3 adsorption-desorption procedure was repeated 8 times over a period of 40 days with the same bioreactor. Furthermore, repeated use of the GPIIb/IIIa bioreactor on the same day was investigated. Leakage of GPIIb/IIIa from the bioreactor after 7E3 desorption was also examined.
Preliminary in vivo, proof-of-concept of the bioreactor approach in rats
Female Sprague-Dawley rats, 200 -250 g, were used for in vivo testing of the feasibility of the bioreactor approach. The aortal artery and the jugular vein of the rat were cannulated, and to the cannulas a hollow fiber bioreactor was attached to form a simple extracorporeal bypass loop. A dose of 4 mg/kg of 7E3 was administered via the jugular vein cannula of the rat to induce thrombocytopenia. Control animals were dosed with an equal volume of sterile saline. Extracorporeal circulation through the bioreactor was initiated 1 h after administration of 7E3 (or saline), when platelet counts are expected to be 15-25% of initial values (i.e., in 7E3-treated animals). Heparin (250 mg/mL) was administered via the jugular vein cannula to prevent coagulation in the bioreactor and extracorporeal loop. Animals were tested in three groups: 1) a control group consisting of rats receiving 7E3; 2) a second control group of rats connected with an albumin-bioreactor and receiving 7E3; and 3) a treatment group of rats connected with the GPIIb/IIIa bioreactor and receiving the 7E3 antiplatelet antibody. Because this was a preliminary proof-of-concept investigation in animals, each group consisted of only three rats.
The blood was circulated through the hollow fiber device at a flow rate of 3 mL/min for 1 h. Platelet counts were determined in PLT rich plasma by using a Z1-Dual Coulter Counter fitted with a 70-mm aperture tube, just before dosing and at 1, 3, 6, 12, and 24 h after dosing. Concentrations of 7E3 were measured by using the ELISA assay. 
RESULTS AND DISCUSSION
Activation of hydroxyl-containing polymers with epichlorohydrin in alkaline medium has been used widely for the preparation of adsorbents for bio-specific affinity chromatography. 35 To optimize the functionality of the GPIIb/IIIa bioreactor, the effects of several parameters on the loading and adsorption capacity of the bioreactor were examined.
Optimization of GPIIbIIIa immobilization
Effects of epichlorohydrin concentration on hollow fiber activation Solutions (10 mL) containing various concentrations of epichlorohydrin were circulated through the hollow fiber bioreactors at 40°C for 2 h. Figure 3 shows the amount of epoxy groups on the bioreactor increased with increasing epichlorohydrin concentrations until a plateau was reached. Indeed, by using 1.0-g hollow fibers, as much as 30 M hydroxyl groups could be activated when a 1.25% epichlorohydrin solution was used. The solution that contained 0.5% epichlorohydrin solution was found to yield sufficient activation (i.e., 26 M epoxy per gram fiber) and, therefore, was used in subsequent experiments.
Effect of temperature and duration of coupling on GPIIb/IIIa loading The GPIIb/IIIa coupling reaction was carried out under varying conditions as listed in Table I . The amount of GPIIb/IIIa coupled to the bioreactor depended on both the coupling temperature and duration. Higher amounts of GPIIb/IIIa loading were observed as the coupling temperature and/or the coupling time are increased. A maximum of 1.624 mg of GPIIb/IIIa per gram of fiber was obtained when the coupling reaction was carried out at 90°C over 6 h. When conducted at 70°C over 6 h, the coupling yield was approximately 85% of the maximum obtained at 90°C. Although immobilized GPIIb/IIIa was found to be relatively stable under extreme experimental conditions, these exceedingly high temperatures (e.g., Ͼ70°C), nevertheless, introduced a significant degree of denaturation of the coupled GPIIb/IIIa (data not shown). On the other hand, room temperature was found to yield a low GPIIb/IIIa loading; Ͻ23% of the maximum loading was attained even with coupling times as long as 72 h. Therefore, the optimal conditions for GPIIb/IIIa coupling were selected at 40°C for 12 h, simply because such conditions provided a yield of 90% compared to the maximum value. In addition, these conditions did not elicit any obvious impairment with regard to the binding affinity of the coupled GPIIb/IIIa toward 7E3.
Effect of coupling pH on GPIIb/IIIa loading
The optimum pH for GPIIb/IIIa coupling was examined by varying pH of the coupling buffers while the coupling conditions were set at 40°C for 12 h. Figure 4 shows that there was a strong dependence between the amount of GPIIb/IIIa coupled and the pH in the coupling buffer. On the basis of these results, the optimum pH for GPIIb/IIIa coupling was determined to be 8.3.
Effect of concentration of coupling buffer on GPIIb/ IIIa loading
To evaluate the effect of the buffer concentration on coupling efficiency, PBS buffers (pH 8.3) of varying concentrations were used while maintaining the coupling reactions at 40°C for 12 h. Figure 5 shows that the optimum buffer concentration was 0.15M PBS buffer.
Effect of GPIIb/IIIa concentrations on loading
The effects of the GPIIb/IIIa concentrations in the coupling solution on GPIIb/IIIa loading were studied in the range of 0 -1 mg/mL. Figure 6 shows that the amount of coupled GPIIb/IIIa increased with increasing GPIIb/IIIa concentration but reached a maximum at 0.5 mg/mL. However, further increase in the GPIIb/IIIa concentration resulted in a decrease in the amount of coupled GPIIb/IIIa, a phenomenon that was probably attributed to the high viscosity in the coupling solution. Therefore, the optimum GPIIB/IIIa concentration to be used in the coupling reaction was determined to be 0.5 mg/mL.
In vitro characterization of the GPIIb/IIIa bioreactor
Adsorption and desorption of 7E3 antibodies by the GPIIb/IIIa bioreactor
To test the ability of the GPIIb/IIIa bioreactor in removing 7E3 antibodies, solutions containing 0.25 mg/mL 7E3 were circulated through the bioreactors prepared in Figure 6 with different GPIIb/IIIa loadings at 37°C for 20 min. The results also plotted in show that the adsorption capacity of the bioreactor toward 7E3 increased with the increase of the GPIIb/IIIa loading in these bioreactors. A maximum 7E3 adsorption capacity of 1.90 mg/g fiber was observed for the bioreactor containing the maximum loading of 1.46 mg GPIIb/IIIa/g fibers. In comparison, the nonspecific 7E3 adsorption onto a sham bioreactor was only 0.17 mg/g fibers. Desorption of 7E3 from the GPIIb/IIIa bioreactor was also examined. Up to 93% of the adsorbed 7E3 was recovered from the bioreactor after four cycles of washings using 0.1M aminoacetic acid as the eluting agent. The elution of the bioreactor by aminoacetic acid likely changed the charges or, in other words, the isoelectric point of GPIIb/IIIa side groups, resulting in the detachment of 7E3 from the bioreactor. It should be noted that there was no detectable GPIIb/IIIa release from the bioreactor, indicating that GPIIb/IIIa molecules were stably and covalently immobilized to the epichlorohydrin-activated hollow fibers. With these desorption results, it was concluded that aminoacetic acid was a suitable agent to regenerate an already used GPIIb/IIIa bioreactor.
Stability and reusability of the GPIIb/IIIa bioreactor
To evaluate the stability and shelf-life of the bioreactor, leakage of GPIIb/IIIa from the bioreactor was examined by filling the interior of the bioreactor with PBS buffer (pH 7.4) and then storing it at room temperature for 4 days. At specific time intervals, 100 L of the filling solution was withdrawn to determine the degree of leakage of GPIIb/IIIa. Data showed that, on average, Ͻ1% of the initially loaded GPIIb/IIIa was leached off from the bioreactor after each day of storage, and a total of 3% of the initially loaded GPIIb/IIIa were lost during the entire span of 4 days of storage. Hence, the GPIIb/IIIa bioreactor thus prepared appears to possess a reasonable shelf-life for its potential clinical application.
To evaluate the reusability of the GPIIb/IIIa bioreactor, the 7E3 adsorption/desorption cycle discussed above was repeated six times over a period of 20 days (i.e., one cycle every 4 days) with the same bioreactor. Results showed that the capacity of the bioreactor toward 7E3 adsorption was reduced by an approximate rate of 2% per cycle of reuse. At the 20-day mark, 87% of the initial 7E3 adsorption capacity of the bioreactor remained.
To further assess the reusability of the GPIIb/IIIa bioreactor on a daily basis, the adsorption-desorption cycle was repeated three times over a 1-day period with the same bioreactor. Results showed that there was no statistically significant reduction in the adsorption capacity of the GPIIb/IIIa bioreactor. By compounding these findings together, it was concluded that the reduction in adsorption capacity of the bioreactor was probably less likely due to the experimental conditions during its usage, but more to do with the storage time.
Preliminary in vivo proof-of-concept studies in rats
Very preliminary proof-of-concept type of investigation was carried out on rats to show the feasibility of the bioreactor approach in treating ITP. Thrombocytopenia was induced in rats by administration, via the jugular vein cannula of the animal, of a dose of 4 mg/kg of 7E3. The ITP-induced rats were then distributed into three subgroups (three rats per group): 1) control group in which the rats were connected with a sham bioreactor; 2) experimental group in which the rats were connected with a GPIIb/IIIa bioreactor; and 3) another control group in which the rats were connected with an albumin-linked bioreactor to determine the degree of nonspecific adsorption of 7E3 onto the hollow fiber-based device. Extracorporeal circulation through the bioreactor was initiated 1 h after administration of 7E3. Figure 7 presents a representative picture that illustrates the trend of changes in platelet counts in animals in response to the bioreactor treatment. As seen, 1 h after 7E3 injection, PLT counts in all of the animals were reduced to 15-25% of their initial values, a typical 7E3-induced thrombocytopenic response in rats as reported elsewhere. 36 In both control groups, the PLT counts continued to remain exceedingly low over at least 12 h and then started to slightly rebound gradually. These results suggested a sustained PLT destruction due to the presence of the 7E3 antibodies. It appeared that there was very limited nonspecific adsorption of 7E3 on the hollow fiber-based bioreactor, because the albumin-coated bioreactor yielded similar PLT destruction as that of the sham bio- reactor. In sharp contrast, rats that received the GPIIb/ IIIa bioreactor treatment displayed a remarkably rapid rebound in PLT counts, because the PLT count completely returned to the initial healthy level that was measured before any bioreactor treatment (Fig. 7) .
Measurements of the blood-free 7E3 concentrations of the treated animals by using the ELISA assay yielded comparable results. Five hours after the bioreactor treatment, 7E3 concentrations in the sham and albumin bioreactor-treated groups were reduced by 20% and 25%, respectively. In contrast, the 7E3 concentration in the GPIIb/IIIa bioreactor-treated rats was markedly reduced by 50%. At the 24-h mark after the treatment, approximately 80% of the administered 7E3 was removed by the GPIIb/IIIa bioreactor. By correlating these results with those seen in Figure 7 in the change of PLT counts, it is obvious that specific removal of the 7E3 antibodies would significantly retard the destruction of PLT, thereby providing a useful means to combat ITP.
It should be pointed out that, in practice, the use of an extracorporeal GPIIb/IIIa bioreactor could never completely (i.e., 100%) deplete the 7E3 autoantibodies produced in ITP. This is because the extracorporeal circuit only represents one of the many branches involved in blood circulation in the body. Hence, when the bioreactor-filtered blood returns to the patient, this specific 7E3-free bloodstream will be mixed with blood from other branches that contain 7E3. As a consequence, the concentration of 7E3 can only be reduced to a minimum value regardless of the GPIIb/IIIa bioreactor efficiency and number of blood circulation cycles. On the other hand, based on the preliminary results shown in Figure  7 , it may not be necessary to achieve a 100% antiplatelet antibody removal.
To examine the hematological effects of the bioreactor treatment, the red blood cell (RBC) count, white blood cell (WBC) count, and total hemoglobin content in the treated animals were analyzed. As expected, the RBC count and total hemoglobin content remained virtually unchanged over the entire course of experiments for all of the three animal groups. It is of interest that the WBC counts in both the control groups (i.e., animals treated with a sham or an albumin bioreactor) decreased to about 20% of their initial values 1 h after the treatment and then returned to the initial values approximately 9 h after the treatment. On the other hand, WBC counts in the GPIIb/IIIa-treated rats were only reduced to 50% of their initial values 1 h after the treatment and then rebounded rapidly to the initial values within a mere 5 h after the GPIIb/IIIa treatment.
CONCLUSIONS
Given the evidence that antiplatelet antibodies (APAb) are responsible for the increased rate of PLT destruction observed in ITP, it is of no surprise that recently increased attention has been given to approaches that will lead to an accelerated removal of these pathogenic antibodies. Indeed, the immunoadsorptive plasmapheresis method by using the PROSORBA column has been approved by the FDA for clinical trials. 24, 25 Despite some clinical promise, a recent ITP "practice guideline" prepared by a panel of the American Society of Hematology listed Protein-A therapy for refractory ITP patients (i.e., refractory to prednisone and splenectomy) as a low preference therapy compared with IVIG. 1 This low preference given to Protein-A plasmapheresis was apparently attributed to the nonspecific nature of this therapy; all IgG would be extracted from plasma, thereby increasing the patient's susceptibility to opportunistic infections. To this regard, the proposed approach possesses the potential to overcome all these shortcomings associated with the PROSORBA approach concomitantly. First, the GPIIb/IIIa bioreactor will specifically remove APAb, and thus patients will not be immunocompromised through removal of nonpathogenic IgG. Second, the new system does not use Protein-A or silica, two components that have been known to cause thrombosis after their leaching from the PROSORBA column and into the patient's blood stream. Third, unlike the PROSORBA device that is established on silica gels, the proposed system is built on cellulose hollow fibers. A hollow fiber-based bioreactor offers unmatched advantages over a particulate-based device because it is nonresistant to blood flow and does not require separation of blood components during its operation.
Overall, the preliminary findings presented in this article were extremely promising, implicating that the development of a highly improved new alternative in treating ITP is reasonably plausible. Continued studies to further optimize the loading and adsorption capacity of this GPIIb/IIIa bioreactor, as well as to confirm the real-time feasibility of this approach via extensive animal testing, are currently underway in our laboratory.
